Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Key Terms

homologous recombination deficiency medical

A condition in which a cell’s ability to fix certain types of DNA damage is impaired, like a zipper that can’t close properly after being pulled apart. Investors care because tumors with this flaw are often more sensitive to specific drugs and diagnostic tests, making related treatments, companion diagnostics, and clinical trial results potentially decisive for a company’s drug value and future revenue.

parp inhibitors medical

PARP inhibitors are a class of cancer drugs that block an enzyme cells use to repair damaged DNA, effectively preventing cancer cells from fixing themselves and causing them to die. Investors watch them because their clinical approvals, safety profiles, patent status, and tests that identify which patients will benefit determine market size and revenue potential—much like backing a tool that only works on certain problems but can be very valuable when it does.

logistic regression technical

Logistic regression is a statistical tool that estimates the probability of a two-outcome event—such as default vs. non-default, approval vs. rejection, or success vs. failure—based on several input factors. Investors care because it turns complex data (like financial ratios, patient characteristics, or market signals) into a simple likelihood score, similar to weighing pros and cons to decide yes/no, which helps assess risk, value, and decision thresholds.

transcriptome medical

The transcriptome is the complete set of RNA molecules produced by a cell or tissue at a given moment — the working messages copied from DNA that tell the cell which proteins to make. For investors, it matters because this “activity snapshot” reveals which genes are turned on or off, helping identify drug targets, biomarkers, patient groups, and potential commercial value of therapies or diagnostics; think of it as a playlist showing what a cell is actively listening to.

schedule 13g/a regulatory

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

rule 10b5-1 trading plan regulatory

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

s-3asr regulatory

A Form S-3ASR is a pre-approved registration that lets an eligible public company load a shelf of securities it may sell later without repeating a full regulatory review each time. Think of it like a pre-authorized credit line for issuing stocks or bonds: it gives the company fast, flexible access to raise money, which matters to investors because it can signal financial readiness but also means potential share dilution or swift changes in capital structure.

atm prospectus financial

A prospectus for an "at-the-market" (ATM) offering explains a company’s plan to sell newly issued shares directly into the open market over time, at prevailing prices, through one or more broker-dealers. Investors should care because it creates a standing ability for the company to raise cash quickly and incrementally—like an open tab the company can draw on—which can dilute existing shareholders and affect share price and supply.

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays.

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike traditional DNA tests that analyze static "genomic scars"—which may persist even after a patient develops drug resistance—this RNA-based approach provides a dynamic, real-time assessment of a tumor’s functional status.

By analyzing gene expression rather than structural DNA damage, the algorithm can detect HRD in patients and cancer types where genomic scarring is rare or difficult to identify. This advanced methodology allows the model to capture HRD status in patients who might be missed by DNA-based assays, significantly expanding the population that can be identified for potentially life-saving therapies.

A real-world validation study demonstrates that HRD-RNA positive metastatic pancreatic patients treated with first line platinum-based regimens showed a significant reduction in mortality risk compared to those receiving non-platinum first line therapies. These findings, including the complete supporting data, will be published later this year.

“Our HRD-RNA algorithm gives physicians a critical tool to better inform treatment decisions,” said Halla Nimeiri, MD, Chief Development Officer at Tempus. “By looking at the transcriptome, we can identify a functional HRD status that is more dynamic than what can be seen in the genome alone. This work exemplifies how Tempus is leveraging its AI platform and vast repository of data to create clinical solutions with real-world impact.”

HRD-RNA is currently available for research use only in the detection of HRD status within solid tumor patient populations and for the identification of patients likely to respond to platinum regimens or PARP inhibitor therapy. Clinical availability is expected later this year.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. Other than statements of historical facts, all statements contained in this press release are forward-looking statements, including, but not limited to, statements regarding the benefits of the HRD-RNA algorithm in research and clinical care. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218676812/en/

Hanah Heintzelman

hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.